CCM
Cutter Capital Management Portfolio holdings
AUM
$230M
This Quarter Return
+13.7%
1 Year Return
+11.51%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$339M
AUM Growth
+$339M
(+3.2%)
Cap. Flow
-$11.9M
Cap. Flow
% of AUM
-3.5%
Top 10 Holdings %
Top 10 Hldgs %
55.99%
Holding
38
New
12
Increased
4
Reduced
11
Closed
11
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$29.7M |
| 2 |
Agilent Technologies
A
|
$17.9M |
| 3 |
Eli Lilly
LLY
|
$15.3M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$15.2M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
$13.1M |
Top Sells
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$22.5M |
| 2 |
Merck
MRK
|
$21.7M |
| 3 |
Amgen
AMGN
|
$20.1M |
| 4 |
Biogen
BIIB
|
$17.8M |
| 5 |
Kenvue
KVUE
|
$17.5M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$140B
| $30.1M | 8.88% |
359,025
+66,066
| +23% | +$5.54M |
|
|
2
Bristol-Myers Squibb
BMY
$96B
| $29.7M | 8.77% |
+574,057
| New | +$29.7M |
|
3
Royalty Pharma
RPRX
$15.6B
| $18.8M | 5.55% |
664,859
-27,441
| -4% | -$776K |
|
|
4
Agilent Technologies
A
$35.7B
| $17.9M | 5.28% |
+120,485
| New | +$17.9M |
|
5
Ultragenyx Pharmaceutical
RARE
$2.89B
| $15.9M | 4.7% |
286,803
-78,197
| -21% | -$4.34M |
|
6
Legend Biotech
LEGN
$6.41B
| $15.9M | 4.69% |
325,953
-17,177
| -5% | -$837K |
|
7
Insmed
INSM
$28.8B
| $15.8M | 4.65% |
215,884
-11,753
| -5% | -$858K |
|
|
8
Eli Lilly
LLY
$657B
| $15.3M | 4.52% |
+17,299
| New | +$15.3M |
|
|
9
Regeneron Pharmaceuticals
REGN
$61.5B
| $15.2M | 4.49% |
+14,476
| New | +$15.2M |
|
10
Harmony Biosciences
HRMY
$2.12B
| $15.1M | 4.44% |
376,315
+80,544
| +27% | +$3.22M |
|
11
Perrigo
PRGO
$3.27B
| $14.6M | 4.32% |
557,937
+457,937
| +458% | +$12M |
|
|
12
Jazz Pharmaceuticals
JAZZ
$7.75B
| $13.1M | 3.86% |
+117,500
| New | +$13.1M |
|
|
SWTX
13
DELISTED
SpringWorks Therapeutics
SWTX
| $12.1M | 3.58% |
+378,453
| New | +$12.1M |
|
14
Viridian Therapeutics
VRDN
$1.5B
| $11.8M | 3.48% |
+518,677
| New | +$11.8M |
|
15
Sarepta Therapeutics
SRPT
$1.78B
| $10.5M | 3.09% |
83,756
-5,623
| -6% | -$702K |
|
16
BridgeBio Pharma
BBIO
$9.89B
| $10.1M | 2.98% |
396,388
+84,688
| +27% | +$2.16M |
|
17
Axsome Therapeutics
AXSM
$6.05B
| $9.51M | 2.81% |
+105,767
| New | +$9.51M |
|
18
Agios Pharmaceuticals
AGIO
$2.19B
| $8.29M | 2.45% |
+186,623
| New | +$8.29M |
|
19
Iovance Biotherapeutics
IOVA
$807M
| $8.23M | 2.43% |
+876,009
| New | +$8.23M |
|
20
Intellia Therapeutics
NTLA
$1.22B
| $8.03M | 2.37% |
+390,622
| New | +$8.03M |
|
21
Vera Therapeutics
VERA
$1.38B
| $7.64M | 2.26% |
172,876
-57,124
| -25% | -$2.52M |
|
22
Arcellx
ACLX
$3.85B
| $7.5M | 2.22% |
89,863
-97,137
| -52% | -$8.11M |
|
23
Avidity Biosciences
RNA
$5.99B
| $7.39M | 2.18% |
+160,947
| New | +$7.39M |
|
24
BioCryst Pharmaceuticals
BCRX
$1.74B
| $6.07M | 1.79% |
798,137
-1,177,161
| -60% | -$8.95M |
|
25
Enliven Therapeutics
ELVN
$1.2B
| $5.31M | 1.57% |
207,896
-15,089
| -7% | -$385K |
|